Catharina Olivius1, Kerstin Landin-Wilhelmsen2,3, Daniel S Olsson2,3, Gudmundur Johannsson2,3, Åsa Tivesten2,3. 1. Department of Medicine, Hospital of Halland, Tölövägen 3, 434 80, Kungsbacka, Sweden. catharina.olivius@regionhalland.se. 2. Department of Endocrinology, Sahlgrenska University Hospital, Gothenburg, Sweden. 3. Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Abstract
PURPOSE: Women with hypopituitarism have increased morbidity and mortality, and hypogonadism has been suggested to be a contributing mechanism. The purpose of this study was to investigate the prevalence of central hypogonadism and hypoandrogenism in women with hypopituitarism at a single Swedish center. METHODS: All consecutive women (n = 184) who commenced growth hormone (GH) replacement therapy at Sahlgrenska University Hospital in Gothenburg between 1995 and 2015 were included. In accordance with the Endocrine Society Clinical Practice Guidelines, strict criteria, based on menstrual history combined with laboratory measurements, were used to define central hypogonadism. Hypoandrogenism was defined as subnormal levels of dehydroepiandrosterone sulfate and/or androstenedione. RESULTS: Central hypogonadism was present in 78% of the women, in 75% of those ≤ 52 years and in 82% of those > 52 years of age. Hypoandrogenism was found in 61% of all the women and in 92% of those with adrenocorticotropic hormone (ACTH) deficiency. The estrogen substitution rate in hypogonadal women ≤ 52 years was lower than the hormonal substitution rate in the other pituitary hormone axes (74% versus 100%, P < 0.001). The use of estrogen substitution tended to decrease between 2000 and 2016. Few women received androgen treatment. CONCLUSIONS: In this first study of hypogonadism in women with hypopituitarism, using stringent diagnostic criteria for hypogonadism, the prevalence of central hypogonadism and low androgen levels was high and estrogen substitution was insufficient. Further studies are needed to elucidate the importance of hypogonadism and insufficient sex steroid replacement for the increased morbidity in hypopituitary women.
PURPOSE:Women with hypopituitarism have increased morbidity and mortality, and hypogonadism has been suggested to be a contributing mechanism. The purpose of this study was to investigate the prevalence of central hypogonadism and hypoandrogenism in women with hypopituitarism at a single Swedish center. METHODS: All consecutive women (n = 184) who commenced growth hormone (GH) replacement therapy at Sahlgrenska University Hospital in Gothenburg between 1995 and 2015 were included. In accordance with the Endocrine Society Clinical Practice Guidelines, strict criteria, based on menstrual history combined with laboratory measurements, were used to define central hypogonadism. Hypoandrogenism was defined as subnormal levels of dehydroepiandrosterone sulfate and/or androstenedione. RESULTS:Central hypogonadism was present in 78% of the women, in 75% of those ≤ 52 years and in 82% of those > 52 years of age. Hypoandrogenism was found in 61% of all the women and in 92% of those with adrenocorticotropic hormone (ACTH) deficiency. The estrogen substitution rate in hypogonadal women ≤ 52 years was lower than the hormonal substitution rate in the other pituitary hormone axes (74% versus 100%, P < 0.001). The use of estrogen substitution tended to decrease between 2000 and 2016. Few women received androgen treatment. CONCLUSIONS: In this first study of hypogonadism in women with hypopituitarism, using stringent diagnostic criteria for hypogonadism, the prevalence of central hypogonadism and low androgen levels was high and estrogen substitution was insufficient. Further studies are needed to elucidate the importance of hypogonadism and insufficient sexsteroid replacement for the increased morbidity in hypopituitary women.
Entities:
Keywords:
Androgens; Estrogen replacement therapy; Estrogens; Hypogonadism; Hypopituitarism; Women
Authors: Sundeep Khosla; B Lawrence Riggs; Richard A Robb; Jon J Camp; Sara J Achenbach; Ann L Oberg; Peggy A Rouleau; L Joseph Melton Journal: J Clin Endocrinol Metab Date: 2005-07-05 Impact factor: 5.958
Authors: Sina Jasim; Fares Alahdab; Ahmed T Ahmed; Shrikant Tamhane; Larry J Prokop; Todd B Nippoldt; M Hassan Murad Journal: Endocrine Date: 2016-11-05 Impact factor: 3.633
Authors: Daniel S Olsson; Eva Andersson; Ing-Liss Bryngelsson; Anna G Nilsson; Gudmundur Johannsson Journal: J Clin Endocrinol Metab Date: 2014-11-06 Impact factor: 5.958
Authors: Helene Holmer; Johan Svensson; Lars Rylander; Gudmundur Johannsson; Thord Rosén; Bengt-Ake Bengtsson; Marja Thorén; Charlotte Höybye; Marie Degerblad; Margareta Bramnert; Erik Hägg; Britt Edén Engström; Bertil Ekman; Karl-Göran Thorngren; Lars Hagmar; Eva-Marie Erfurth Journal: J Bone Miner Res Date: 2007-12 Impact factor: 6.741
Authors: Cathleen M Rivera; Brandon R Grossardt; Deborah J Rhodes; Robert D Brown; Véronique L Roger; L Joseph Melton; Walter A Rocca Journal: Menopause Date: 2009 Jan-Feb Impact factor: 2.953
Authors: K K Miller; B M K Biller; C Beauregard; J G Lipman; J Jones; D Schoenfeld; J C Sherman; B Swearingen; J Loeffler; A Klibanski Journal: J Clin Endocrinol Metab Date: 2006-02-14 Impact factor: 5.958